EUCTR2004-000742-21-IT进行中（未招募）不适用
OPEN-LABEL, MULTICENTRE, PHASE 2 STUDY EVALUATING THE UTILITY OF 123I-nIBG SCINTIGRAPHYFOR ASSESSING ARRHYTHMIC RISK AS COMPARED TO ELECTROPHYSIOLOGY TESTING IN SUBJECTS WITH LEFT VENTRICULAR DYSFUNCTIO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCEROPERABLE PROSTATE CANCERMedDRA version: 6.1Level: PTClassification code 10060862EUCTR2004-000495-14-ITASTRAZENECA
进行中（未招募）
不适用
OPEN LABEL, MULTICENTER, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IMC-11F8 IN COMBINATION WITH 5-FU/FA AND OXALIPLATIN (MODIFIED FOLFOX-6) IN PATIENTS WITH TREATMENT-NAÏVE, LOCALLY-ADVANCED OR METASTATIC COLORECTAL CANCER - IMCL CP11-0602EUCTR2006-003147-23-BEImClone LLC40
进行中（未招募）
1 期
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian CancerEUCTR2008-005576-26-GBektar Therapeutics178
招募中
1 期
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring ChronicChronic lymphocytic leukemia recurrentCTIS2023-504599-10-00AbbVie Deutschland GmbH & Co. KG75
进行中（未招募）
1 期
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based TreatmentEUCTR2008-005577-36-BEektar Therapeutics70